Hefty Orkambi commercial spend helps Vertex pick up the growth pace

Vertex CEO Jeffrey Leiden

Vertex has pumped up the launch for slow-starting cystic fibrosis med Orkambi--but it took some serious spending to do it.

Wednesday, the Massachusetts biotech reported SG&A costs that increased 23% year-over-year. While some of that spend went toward Vertex’s CF pipeline, the company put the rest behind “commercial support for Orkambi,” Leerink Partners analyst Geoffrey Porges wrote in a research note Thursday. But it paid off, with the med’s revenues picking up by 10% over the year-ago quarter to hit a $245 million mark that fell in line with forecasts.

That increase will “likely to come as a relief to investors after a disappointing early slowing in Orkambi’s growth trajectory,” Porges noted, and he also expects the results to provide a tailwind heading into the second half of the year, when execs on the Q2 conference call “repeatedly emphasized that incremental revenue opportunities and regulatory events were likely.”

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Among them: A label expansion for the tandem med to include children aged 6 to 11 with two copies of the delta 508 mutation. The FDA is currently reviewing Vertex’s bid, with a PDUFA date for Sept. 30. And if it wins a green light--an event Porges expects--“we expect to be ready to bring Orkambi to these patients immediately,” CEO Jeffrey Leiden told investors.

While an FDA go ahead could help Vertex reach about 2,400 children in the U.S., there are even more young patients eligible for the therapy in Europe, Leiden estimated, pegging the tally at about 3,400. There, the drugmaker plans to submit its application for approval in the first half of next year, which could result in an early 2018 regulatory clearance.

Though in Europe, it hasn't been all smooth sailing when it comes to snagging reimbursement coverage. Last month, England's cost watchdogs turned down the med and its £104,000 ($147,000) pricetag for routine NHS use.

- read the call transcript

Related Articles:
NICE sticks to its guns and turns down Vertex's Orkambi even as patients plead
NICE gives initial thumbs-down to Vertex's CF combo med Orkambi, citing costs
CF specialists up in arms about $259K price for new Vertex med Orkambi

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.